Lilly Affinitac Launch Supply Will Be Produced By Isis; Deliveries Start In 2003
Executive Summary
Isis will begin building launch supply of the non-small cell lung cancer antisense drug Affinitac in early 2003 under a manufacturing agreement with Lilly announced Oct. 1
You may also be interested in...
Iressa Cross-Over Study Could Show Clinical Benefit, AZ Says; ODAC Is Wary
AstraZeneca believes a controlled, cross-over trial could be used to confirm the sympom benefit of Iressa in refractory non-small cell lung cancer patients, VP-Medical Director of Oncology George Blackledge, MD, said during FDA's Oncologic Drugs Advisory Committee Sept. 24
ClinicalTrials.Gov Lists 22 Lilly Studies; Response To FDA Deadline Is Mixed
Lilly has 22 open protocols listed on the National Library of Medicine's ClinicalTrials.gov website
Lilly/Isis Lung Cancer NDA Possible In 2003; Lymphoma Indication In Phase II
An NDA for the Isis drug 3521, licensed to Eli Lilly, could be submitted for non-small cell lung cancer by 2003.